Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes (DCB-PE)
Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes
Drug eluting balloon angioplasty might be a better alternative than medical treatment or stenting in subjects with plaque erosion, which is the second most common cause of myocardial infarction.
The main objective of this pilot study is to gain clear insights on the effect of percutaneous coronary intervention (PCI) with size matched DCB (SeQuent) as compared to treatment with GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy in a predominantly Caucasian population at 2 days and at 1 year after the procedure.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Prof. Elvin Kedhi, MD PhD
- 电话号码:+1 514-934-1934
- 邮箱:ekedhi@me.com
学习地点
-
-
-
Lubin、波兰
- Miedziowe Centrum Zdrowia SA
-
接触:
- Dr. hab. n. med. Adrian Wlodarczak
- 电话号码:+48 76 846 03 00
- 邮箱:wlodarczakadrian@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patients aged ≥18 years presenting with MI where the culprit de-novo (stent restenosis/thrombosis excluded) lesion has a Thrombolysis in Myocardial Infarction (TIMI) flow of ≥ I with signs of thrombus on angiographic (or CCTA followed by conventional coronary angiography) evaluation located in a native coronary artery (a by-pass graft vessel excluded) addressable by PCI;
OCT criteria (all 4 should be present):
- Presence of thrombus
- Absence of an overt ruptured plaque flap
- Area of stenosis of ≥ 50%
- Presence of atherosclerotic, predominantly lipidic or fibrotic plaque underneath (absence of major calcifications or calcified noduli)
Exclusion Criteria:
- Culprit lesion located or extending in the Left Main coronary artery;
- Presence of large coronary aneurysms;
- Large thrombus burden (extending for more than > 15 mm);
- Patients with severe tortuous lesions (OCT judged not possible);
- Spontaneous coronary dissection is suspected;
- Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5);
- Life expectancy less than 2 years;
- Pregnant or lactating women;
- Patients currently participating in another trial;
Patients that are unable or unwilling to provide consent;
OCT exclusion criteria:
- Overt plaque rupture;
- Thrombosed protruding calcified noduli;
- Predominantly calcific lesions with calcium arc > 180° in the target segment;
- Presence of calcium plaque of > 0.4 mm thick;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:PCI with size matched DCB
PCI with size matched drug-coated balloon
|
Subjects will be treated with PCI with size matched DCB (SeQuent)
|
|
安慰剂比较:GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Optical Coherence Tomography (OCT)-assessed Minimum Lumen Area (MLA) during the control procedure
大体时间:Day 2-3
|
Day 2-3
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Coronary Computed Tomography Angiography (CCTA) assessed MLA at 1-year
大体时间:1 Year
|
1 Year
|
|
|
Target Lesion Failure (TLF) at 1-year
大体时间:1 Year
|
TLF is defined as Cardiac death, Target Vessel-MI (TV-MI), and Clinically-Driven Target Lesion Revascularization (CD-TLR)
|
1 Year
|
|
TLF at 2-years
大体时间:2 Years
|
TLF is defined as Cardiac death, TV-MI, and CD-TLR
|
2 Years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
CCTA-assessed plaque burden at baseline
大体时间:Baseline
|
Baseline
|
|
|
CCTA-assessed plaque burden post PCI
大体时间:1 Week
|
1 Week
|
|
|
CCTA-assessed plaque burden at 1-year
大体时间:1 Year
|
1 Year
|
|
|
CCTA-assessed lipid pool volume at baseline
大体时间:Baseline
|
Baseline
|
|
|
CCTA-assessed lipid pool volume post PCI
大体时间:1 Week
|
1 Week
|
|
|
CCTA-assessed lipid pool volume at 1-year
大体时间:1 Year
|
1 Year
|
|
|
Computed Tomography Fractionated Flow Reserve (CT-FFR) at baseline
大体时间:Baseline
|
Baseline
|
|
|
CT-FFR at 1-year
大体时间:1 Year
|
1 Year
|
|
|
Shear stress at lesion level at baseline measured by Elucid software
大体时间:Baseline
|
Baseline
|
|
|
Shear stress at lesion level at 1-year measured by Elucid software
大体时间:1 Year
|
1 Year
|
|
|
OCT-assessed thrombus volume at baseline
大体时间:Baseline
|
Baseline
|
|
|
OCT-assessed thrombus volume at control procedure
大体时间:Day 2-3
|
Day 2-3
|
|
|
OCT-assessed area of stenosis post index procedure
大体时间:Periprocedural
|
Periprocedural
|
|
|
OCT-assessed area of stenosis post control procedure
大体时间:Day 2-3
|
Day 2-3
|
|
|
OCT-assessed lumen gain
大体时间:Periprocedural and Day 2-3
|
Difference between control and index MLA
|
Periprocedural and Day 2-3
|
|
OCT-assessed lipid arc at control procedure
大体时间:Day 2-3
|
Day 2-3
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.